NYSE:PBH - Prestige Consumer Healthcare Stock Price, Forecast & News

Prestige Consumer Healthcare's stock was trading at $35.91 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, PBH stock has increased by 1.4% and is now trading at $36.40. View which stocks have been mosted impacted by Coronavirus.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Prestige Consumer Healthcare in the last year. There are currently 2 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Prestige Consumer Healthcare.

Prestige Consumer Healthcare is scheduled to release its next quarterly earnings announcement on Thursday, May 14th 2020. View our earnings forecast for Prestige Consumer Healthcare.

Prestige Consumer Healthcare Inc (NYSE:PBH) released its quarterly earnings data on Thursday, February, 6th. The company reported $0.81 EPS for the quarter, topping analysts' consensus estimates of $0.75 by $0.06. The business earned $241.60 million during the quarter, compared to analysts' expectations of $240.34 million. Prestige Consumer Healthcare had a positive return on equity of 13.17% and a negative net margin of 3.57%. The company's quarterly revenue was up .1% on a year-over-year basis. During the same period in the previous year, the business earned $0.73 EPS. View Prestige Consumer Healthcare's earnings history.

Prestige Consumer Healthcare updated its FY20 earnings guidance on Thursday, February, 6th. The company provided EPS guidance of $2.85-2.87 for the period, compared to the Thomson Reuters consensus estimate of $2.82. The company issued revenue guidance of $947-957 million, compared to the consensus revenue estimate of $950.04 million.

5 analysts have issued 1-year price targets for Prestige Consumer Healthcare's stock. Their forecasts range from $43.00 to $106.00. On average, they expect Prestige Consumer Healthcare's stock price to reach $77.67 in the next year. This suggests a possible upside of 113.4% from the stock's current price. View analysts' price targets for Prestige Consumer Healthcare.

News coverage about PBH stock has trended somewhat positive this week, InfoTrie Sentiment Analysis reports. The research firm identifies negative and positive media coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Prestige Consumer Healthcare earned a daily sentiment score of 1.8 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 4.0 out of 10, indicating that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the near term. View the latest news aboutPrestige Consumer Healthcare.

Prestige Consumer Healthcare saw a increase in short interest during the month of March. As of March 13th, there was short interest totaling 7,734,200 shares, an increase of 5.1% from the February 27th total of 7,360,000 shares. Based on an average daily volume of 391,700 shares, the days-to-cover ratio is currently 19.7 days. Approximately 15.5% of the shares of the stock are short sold. View Prestige Consumer Healthcare's Current Options Chain.

Some companies that are related to Prestige Consumer Healthcare include Estee Lauder Companies (EL), Herbalife Nutrition (HLF), Avon Products (AVP), Inter Parfums (IPAR), USANA Health Sciences (USNA), Nu Skin Enterprises (NUS), Medifast (MED), Revlon (REV), Veru (VERU) and Nature's Sunshine Products (NATR).

Based on aggregate information from My MarketBeat watchlists, some companies that other Prestige Consumer Healthcare investors own include Gilead Sciences (GILD), AbbVie (ABBV), Edwards Lifesciences (EW), AT&T (T), Cara Therapeutics (CARA), GW Pharmaceuticals PLC- (GWPH), Rigel Pharmaceuticals (RIGL), Boeing (BA), IBM (IBM) and Johnson & Johnson (JNJ).

Prestige Consumer Healthcare trades on the New York Stock Exchange (NYSE) under the ticker symbol "PBH."

Prestige Consumer Healthcare's stock is owned by a number of retail and institutional investors. Top institutional investors include Champlain Investment Partners LLC (4.73%), Macquarie Group Ltd. (3.98%), Macquarie Group Ltd. (3.98%), FMR LLC (3.79%), ArrowMark Colorado Holdings LLC (3.70%) and State Street Corp (3.54%). Company insiders that own Prestige Consumer Healthcare stock include Jean A Boyko, Paton Brett and Timothy Connors. View institutional ownership trends for Prestige Consumer Healthcare.

PBH stock was sold by a variety of institutional investors in the last quarter, including ArrowMark Colorado Holdings LLC, Goldman Sachs Group Inc., Acadian Asset Management LLC, State of Tennessee Treasury Department, Prudential Financial Inc., Lapides Asset Management LLC, Oxford Asset Management LLP, and Skyline Asset Management LP. View insider buying and selling activity for Prestige Consumer Healthcare.

PBH stock was purchased by a variety of institutional investors in the last quarter, including Norges Bank, Macquarie Group Ltd., Macquarie Group Ltd., Champlain Investment Partners LLC, Wedge Capital Management L L P NC, Man Group plc, Peregrine Capital Management LLC, and Massachusetts Financial Services Co. MA. View insider buying and selling activity for Prestige Consumer Healthcare.

Shares of PBH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of PBH stock can currently be purchased for approximately $36.40.

Prestige Consumer Healthcare has a market capitalization of $1.83 billion and generates $975.78 million in revenue each year. The company earns $-35,800,000.00 in net income (profit) each year or $2.78 on an earnings per share basis. Prestige Consumer Healthcare employs 530 workers across the globe. View additional information about Prestige Consumer Healthcare.

The official website for Prestige Consumer Healthcare is http://www.prestigebrands.com/.

Prestige Consumer Healthcare's mailing address is 660 WHITE PLAINS ROAD SUITE 250, TARRYTOWN NY, 10591. The company can be reached via phone at 914-524-6800 or via email at [email protected]